Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

A large case-control study on vaccination as risk factor for multiple sclerosis.

Hapfelmeier A, Gasperi C, Donnachie E, Hemmer B.

Neurology. 2019 Jul 30. pii: 10.1212/WNL.0000000000008012. doi: 10.1212/WNL.0000000000008012. [Epub ahead of print]

PMID:
31363057
2.

CSF parameters associated with early MRI activity in patients with MS.

Klein A, Selter RC, Hapfelmeier A, Berthele A, Müller-Myhsok B, Pongratz V, Gasperi C, Zimmer C, Mühlau M, Hemmer B.

Neurol Neuroimmunol Neuroinflamm. 2019 May 30;6(4):e573. doi: 10.1212/NXI.0000000000000573. eCollection 2019 Jul.

3.

The neuropathology of fatal encephalomyelitis in human Borna virus infection.

Liesche F, Ruf V, Zoubaa S, Kaletka G, Rosati M, Rubbenstroth D, Herden C, Goehring L, Wunderlich S, Wachter MF, Rieder G, Lichtmannegger I, Permanetter W, Heckmann JG, Angstwurm K, Neumann B, Märkl B, Haschka S, Niller HH, Schmidt B, Jantsch J, Brochhausen C, Schlottau K, Ebinger A, Hemmer B, Riemenschneider MJ, Herms J, Beer M, Matiasek K, Schlegel J.

Acta Neuropathol. 2019 Jul 26. doi: 10.1007/s00401-019-02047-3. [Epub ahead of print]

PMID:
31346692
4.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
5.

Clinical trials in multiple sclerosis: potential future trial designs.

Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O.

Ther Adv Neurol Disord. 2019 May 13;12:1756286419847095. doi: 10.1177/1756286419847095. eCollection 2019. Review.

6.

CSF Protein Concentration Shows No Correlation With Brain Volume Measures.

Wuschek A, Grahl S, Pongratz V, Korn T, Kirschke J, Zimmer C, Hemmer B, Mühlau M.

Front Neurol. 2019 May 3;10:463. doi: 10.3389/fneur.2019.00463. eCollection 2019.

7.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

8.

Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging.

Schmidt P, Pongratz V, Küster P, Meier D, Wuerfel J, Lukas C, Bellenberg B, Zipp F, Groppa S, Sämann PG, Weber F, Gaser C, Franke T, Bussas M, Kirschke J, Zimmer C, Hemmer B, Mühlau M.

Neuroimage Clin. 2019 May 2;23:101849. doi: 10.1016/j.nicl.2019.101849. [Epub ahead of print]

9.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
10.

CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.

Ancau M, Berthele A, Hemmer B.

Expert Opin Biol Ther. 2019 Aug;19(8):829-843. doi: 10.1080/14712598.2019.1611778. Epub 2019 May 24.

PMID:
31027436
11.

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.

Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, Papanastasiou AD, Grimmer T, Gourzis P, Berthele A, Hemmer B, Kübler H, Martin J, Politis A, Perneczky R.

J Alzheimers Dis. 2019;69(1):83-90. doi: 10.3233/JAD-181088.

PMID:
30909232
12.

Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis.

Eichinger P, Schön S, Pongratz V, Wiestler H, Zhang H, Bussas M, Hoshi MM, Kirschke J, Berthele A, Zimmer C, Hemmer B, Mühlau M, Wiestler B.

Radiology. 2019 May;291(2):429-435. doi: 10.1148/radiol.2019181568. Epub 2019 Mar 12.

PMID:
30860448
13.

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.

Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ; International Multiple Sclerosis Visual System Consortium.

Ann Neurol. 2019 May;85(5):618-629. doi: 10.1002/ana.25462. Epub 2019 Apr 10.

PMID:
30851125
14.

Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.

Grahl S, Pongratz V, Schmidt P, Engl C, Bussas M, Radetz A, Gonzalez-Escamilla G, Groppa S, Zipp F, Lukas C, Kirschke J, Zimmer C, Hoshi M, Berthele A, Hemmer B, Mühlau M.

Mult Scler Relat Disord. 2019 Apr;29:124-129. doi: 10.1016/j.msard.2019.01.042. Epub 2019 Jan 28.

PMID:
30711877
15.

Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2019 Jan 15;92(3):151. doi: 10.1212/WNL.0000000000006774. No abstract available.

PMID:
30643034
16.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

17.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
18.

A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015.

Daltrozzo T, Hapfelmeier A, Donnachie E, Schneider A, Hemmer B.

Front Neurol. 2018 Oct 30;9:871. doi: 10.3389/fneur.2018.00871. eCollection 2018.

19.

Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity.

Knier B, Hiltensperger M, Sie C, Aly L, Lepennetier G, Engleitner T, Garg G, Muschaweckh A, Mitsdörffer M, Koedel U, Höchst B, Knolle P, Gunzer M, Hemmer B, Rad R, Merkler D, Korn T.

Nat Immunol. 2018 Dec;19(12):1341-1351. doi: 10.1038/s41590-018-0237-5. Epub 2018 Oct 29.

20.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

21.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

22.

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnes P, Mauri C, Jury EC; ABIRISK Consortium.

JCI Insight. 2018 Jun 7;3(11). pii: 99274. doi: 10.1172/jci.insight.99274. eCollection 2018 Jun 7.

23.

Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis.

Lechner P, Buck D, Sick L, Hemmer B, Multhoff G.

Mult Scler J Exp Transl Clin. 2018 May 2;4(2):2055217318767192. doi: 10.1177/2055217318767192. eCollection 2018 Apr-Jun.

24.

Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.

Zimmermann HG, Knier B, Oberwahrenbrock T, Behrens J, Pfuhl C, Aly L, Kaminski M, Hoshi MM, Specovius S, Giess RM, Scheel M, Mühlau M, Bellmann-Strobl J, Ruprecht K, Hemmer B, Korn T, Paul F, Brandt AU.

JAMA Neurol. 2018 Sep 1;75(9):1071-1079. doi: 10.1001/jamaneurol.2018.1011.

25.

Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2018 May 15;90(20):e1815-e1821. doi: 10.1212/WNL.0000000000005529. Epub 2018 Apr 18.

26.

Multiple sclerosis.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O.

Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23. Review.

PMID:
29576504
27.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
28.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9.

PMID:
29521573
29.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

30.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
31.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
32.

Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.

Feucht N, Maier M, Lepennetier G, Pettenkofer M, Wetzlmair C, Daltrozzo T, Scherm P, Zimmer C, Hoshi MM, Hemmer B, Korn T, Knier B.

Mult Scler. 2019 Feb;25(2):224-234. doi: 10.1177/1352458517750009. Epub 2018 Jan 5.

PMID:
29303033
33.

Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients.

Kalluri SR, Grummel V, Hracsko Z, Pongratz V, Pernpeintner V, Gasperi C, Buck D, Hemmer B; ABIRISK Consortium.

J Autoimmun. 2018 Mar;88:83-90. doi: 10.1016/j.jaut.2017.10.003. Epub 2017 Oct 21.

PMID:
29066027
34.

Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging.

Righart R, Biberacher V, Jonkman LE, Klaver R, Schmidt P, Buck D, Berthele A, Kirschke JS, Zimmer C, Hemmer B, Geurts JJG, Mühlau M.

Ann Neurol. 2017 Oct;82(4):519-529. doi: 10.1002/ana.25020. Epub 2017 Sep 16.

35.

Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.

Righart R, Schmidt P, Dahnke R, Biberacher V, Beer A, Buck D, Hemmer B, Kirschke JS, Zimmer C, Gaser C, Mühlau M.

PLoS One. 2017 Jul 6;12(7):e0179590. doi: 10.1371/journal.pone.0179590. eCollection 2017.

36.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

37.

The spectrum of aseptic central nervous system infections in southern Germany - demographic, clinical and laboratory findings.

Kaminski M, Grummel V, Hoffmann D, Berthele A, Hemmer B.

Eur J Neurol. 2017 Aug;24(8):1062-1070. doi: 10.1111/ene.13335. Epub 2017 Jun 21.

PMID:
28636287
38.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

39.

CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder.

Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H, Dzieciatkowska M, Ritchie AM, Hemmer B, Owens GP, Bennett JL.

Ann Clin Transl Neurol. 2017 May 9;4(6):369-380. doi: 10.1002/acn3.418. eCollection 2017 Jun.

40.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

41.

Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.

Biberacher V, Schmidt P, Selter RC, Pernpeinter V, Kowarik MC, Knier B, Buck D, Hoshi MM, Korn T, Berthele A, Kirschke JS, Zimmer C, Hemmer B, Mühlau M.

Mult Scler. 2018 Jul;24(8):1115-1125. doi: 10.1177/1352458517712078. Epub 2017 May 25.

PMID:
28539075
42.

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis.

Knier B, Leppenetier G, Wetzlmair C, Aly L, Hoshi MM, Pernpeintner V, Biberacher V, Berthele A, Mühlau M, Zimmer C, Hemmer B, Korn T.

JAMA Neurol. 2017 Jul 1;74(7):847-856. doi: 10.1001/jamaneurol.2017.0377.

43.

Corrigendum: Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T.

Nat Immunol. 2017 Mar 22;18(4):474. doi: 10.1038/ni0417-474b. No abstract available.

PMID:
28323263
44.

Daclizumab for the treatment of relapsing-remitting multiple sclerosis.

Herwerth M, Hemmer B.

Expert Opin Biol Ther. 2017 Jun;17(6):747-753. doi: 10.1080/14712598.2017.1304913. Epub 2017 Apr 7.

PMID:
28286970
45.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

46.

Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitations.

Hemmer B, Mühlau M.

Nat Rev Neurol. 2017 Feb;13(2):72-74. doi: 10.1038/nrneurol.2017.2. Epub 2017 Jan 20. Review. No abstract available.

PMID:
28106067
47.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

48.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

49.

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.

Aly L, Hemmer B, Korn T.

Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525. Review.

50.

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T.

Nat Immunol. 2017 Jan;18(1):74-85. doi: 10.1038/ni.3632. Epub 2016 Nov 28. Erratum in: Nat Immunol. 2017 Mar 22;18(4):474.

Supplemental Content

Loading ...
Support Center